Supplementary data for 'Modeling acquired resistance to the second-generation androgen receptor antagonist enzalutamide in the TRAMP model of prostate cancer'.

This copy of the Supplementary Material is subject to the same embargo as the post-print and will be available here from 06/02/21. Content: Model parameterization Vehicle and enzalutamide: -In vitro experiments Figures SMM1 & SMM2 -In vivo experiments (under skin) Figures SMM3 & SMM4 Mathematical model for combo therapies: enzalutamide-everolimus or enzalutamide-cabazitaxel Everolimus: -From in vitro experiments Figures SMM5 & SMM6 -In vivo experiments (under skin) Figure SMM7 Cabazitaxel: -In vitro experiments Figures SMM8 & SMM9 -In vivo experiments (under skin) Figure SMM10 Sensitivity Analysis